Sandor V.
- Country
- Hungary
- Department
- NA
Research Overview
- Phase 3 Randomized Double-Blind Placebo-Controlled Study of KAI-9531 in Adults With Obesity or Overweight and Diabetes
- Evaluation of Obicetrapib on Major Adverse Cardiovascular Events in Atherosclerotic Cardiovascular Disease Patients on Maximal Lipid-Modifying Therapy
- Phase 3 Randomized Study Comparing Asundexian and Apixaban for Stroke Prevention in Atrial Fibrillation Patients at Risk
Data & Insights
Has run more than one trial at 461 of 1078 partner sites.
Specializations
Atherosclerotic Cardiovascular Disease and Lipid Management
Sandor Vangel is involved in clinical research centered on atherosclerotic cardiovascular disease, hyperlipidemia, and broader cardiovascular risk reduction. This includes studies in people with established vascular disease and persistent lipid abnormalities, with attention to outcomes such as major adverse cardiovascular events and LDL cholesterol lowering.
- ASCVD
- Hyperlipidemia
- LDL-C reduction
- Cardiovascular outcomes
His trial activity also extends to prevention-oriented cardiovascular strategies in patients whose current lipid-modifying treatment is not sufficiently effective.
Atrial Fibrillation and Thromboembolic Prevention
Another major area of interest is the prevention of stroke and systemic embolism in atrial fibrillation. The research landscape includes anticoagulation-focused studies comparing therapies intended to reduce thromboembolic risk while also addressing bleeding safety.
- Atrial fibrillation
- Stroke prevention
- Systemic embolism
- Bleeding risk
This therapeutic domain reflects a strong focus on balancing protection from clot-related complications with treatment tolerability in people at elevated cardiovascular risk.
Type 2 Diabetes and Glycaemic Control
Sandor Vangel is actively engaged in studies addressing type 2 diabetes, especially in individuals with inadequate glycaemic control and concurrent overweight or obesity. The research portfolio includes therapies aimed at improving HbA1c, supporting metabolic control, and managing diabetes in the setting of additional cardiometabolic burden.
- Type 2 diabetes
- HbA1c improvement
- Metabolic control
- Overweight and obesity
His involvement also covers diabetes populations with concurrent chronic kidney disease, reflecting interest in cardiometabolic complications that influence long-term disease management.
Obesity, Weight Management, and Metabolic Disease
His clinical trial activity includes a clear emphasis on chronic weight management and treatment of obesity and overweight, including populations with coexisting type 2 diabetes. These studies focus on body weight reduction as a therapeutic target within broader metabolic care.
- Obesity
- Chronic weight management
- Overweight
- Body weight reduction
The research scope also includes agents developed for combined metabolic benefit, linking weight control with improvements in glycaemic and cardiovascular risk profiles.
Chronic Kidney Disease and Hypertriglyceridemia
Sandor Vangel’s research interests further extend to chronic kidney disease in people living with type 2 diabetes and excess body weight, as well as to severe hypertriglyceridemia. These areas highlight involvement in metabolic complications that intersect with cardiovascular and renal risk.
- Chronic kidney disease
- Severe hypertriglyceridemia
- Diabetic kidney disease
- Cardiorenal risk
His trial portfolio includes therapies aimed at addressing lipid disorders and kidney-related surrogate markers in metabolically complex patient groups.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.